# Angiodynamics Inc: Form 10-Q for the period ended Feb 29, 2012

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2012-04-09
- Accepted by EDGAR: Apr 9, 2012, 16:00 ET
- Period: 2012-02-29
- Accession: 0001193125-12-155135
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000119312512155135/d323745d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000119312512155135/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-02-29.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-12-01 to 2012-02-29 | $51.6m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2011-06-01 to 2012-02-29 | $164.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2011-12-01 to 2012-02-29 | $22.2m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2011-06-01 to 2012-02-29 | $69.3m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2011-12-01 to 2012-02-29 | $29.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2011-06-01 to 2012-02-29 | $94.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2011-12-01 to 2012-02-29 | $4.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2011-06-01 to 2012-02-29 | $15.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2011-12-01 to 2012-02-29 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2011-06-01 to 2012-02-29 | $3.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-12-01 to 2012-02-29 | $102.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2011-06-01 to 2012-02-29 | $329.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-12-01 to 2012-02-29 | −$1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2011-06-01 to 2012-02-29 | $858.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-12-01 to 2012-02-29 | −$1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2011-06-01 to 2012-02-29 | $1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-12-01 to 2012-02-29 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2011-06-01 to 2012-02-29 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-12-01 to 2012-02-29 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2011-06-01 to 2012-02-29 | $0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2011-12-01 to 2012-02-29 | 25,129,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2011-06-01 to 2012-02-29 | 25,289,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2011-06-01 to 2012-02-29 | $12.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2011-06-01 to 2012-02-29 | $1.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2012-02-29 | $34.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-02-29 | $211.0m | us-gaap:AssetsCurrent |
| Total assets | at 2012-02-29 | $446.6m | us-gaap:Assets |
| Current liabilities | at 2012-02-29 | $29.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-02-29 | $35.2m | us-gaap:Liabilities |
| Long-term debt | at 2012-02-29 | $6.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2012-02-29 | $295.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2012-02-29 | $411.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,977 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC, including our Form 10-K for the fiscal year ended May 31, 2011 and our quarterly report on Form 10-Q for the fiscal quarter ended November 30, 2011.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### Overview

We are a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease, or PVD, and local oncology therapy options for treating cancer, including radiofrequency ablation, or RFA, systems and surgical resection systems, including NanoKnife Ablation Systems. We design, develop, manufacture and market a broad line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases. Unlike several of our competitors that focus on the treatment of coronary diseases, we believe that we are the only company whose primary focus is to offer a comprehensive product line for the interventional treatment of PVD, tumors and other non-coronary diseases.

Our business is organized into two reportable segments: Vascular and Oncology/Surgery. The Vascular segment, under the direction of a general manager, is responsible for products targeting the venous intervention, dialysis access, thrombus management and peripheral disease markets and has dedicated research and development and sales and marketing personnel assigned to it. The Oncology/Surgery segment, under the direction of a general manager, is responsible for RF Ablation, NanoKnife and Habib product lines and has dedicated research and development and sales and marketing personnel assigned to it.

We sell our broad line of quality devices in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. For the three months and nine months ended February 29, 2012 approximately 15% and 14% of our net sales were from markets outside the United States compared with 12% in both the three and nine months ended February 28, 2011.

Our growth depends in large part on the continuous introduction of new and innovative products, together with ongoing enhancements to our existing products, through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in, research and development. For the three and nine months ended February 29, 2012, our research and development (“R&D”) expenditures were $4.6 million and $15.3 million, respectively, which represented 9% of net sales in each period. Comparable prior year expenditures were $5.3 million and $15.8 million, respectively, or 10% of net sales. We expect to continue to spend considerable amounts on R&D activities in the future; however, downturns in our business could cause us to reduce our R&D spending.

Except to the extent we can further use our cash and short term investments or our equity securities as acquisition capital, we will require additional equity or debt financing to fund any future significant acquisitions.

Several years ago, we expanded our manufacturing and warehousing facilities in Queensbury, New York, to provide us with significantly greater manufacturing and warehousing capacity and to accommodate additional research, development and administrative requirements. We are not currently operating our manufacturing facilities at full capacity. In July 2009, we entered into an agreement to lease, for a ten year period plus 2 five year renewal options, a 52,500 square foot office building in Latham, New York. We commenced occupancy of the facility in Latham in March 2010.

Our ability to further increase our profitability will depend in part on improving gross profit margins. Factors such as changes in our product mix, new technologies and unforeseen price pressures may cause our margins to grow at a slower rate than we have anticipated, or to decline.

### Recent Developments

See Note A to our consolidated financial statements in this Quarterly Report on Form 10-Q for recent developments.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note L to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations

### Three Months ended February 29, 2012 and February 28, 2011

For the third quarter of fiscal 2012, we reported a net loss of $1.8 million, or $(0.07) per diluted common share, on net sales of $51.6 million, compared with net income of $3.8 million, or $0.15 per diluted common share, on net sales of $54.6 million in the third quarter of the prior year.

The following table sets forth certain operating data as a percentage of net sales:

|  | Three Months Ended Feb 29, 2012 | Feb 28, 2011 |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 57.0% | 58.0% |
| Research and development | 8.9% | 9.7% |
| Sales and marketing | 30.6% | 26.6% |
| General and administrative | 8.6% | 8.0% |
| Amortization of intangibles | 4.5% | 4.1% |
| Acquisition, restructuring and other costs, net | 9.8% | 0.0% |
| Operating (loss) income | (5.3%) | 9.6% |
| Other income (expenses) | (0.2%) | (0.3%) |
| Income taxes | (2.2%) | 2.3% |
| Net (loss) income | (3.4%) | 7.0% |

Net sales. Net sales are derived from the sale of our products and related freight charges, less discounts and returns. Net sales of $51.6 million decreased $3.0 million from the $54.6 million reported in the third quarter of fiscal 2011. This change in net sales was primarily attributable to a $2.6 million decline in sales of LC Beads, as our distribution rights to the product ended on December 31, 2011. The balance of the decrease in sales was attributable to a decrease in unit sales of dialysis access catheters, PICCs and conventional Vortex ports, offset by increased unit sales of Venacure/EVLT procedure kits and lasers and Smart ports.

From a reportable segment perspective, Vascular sales decreased 1% from the prior year period to $37.9 million. This decrease was primarily attributable to 2% lower average selling prices in the U.S., decreased unit sales of PICCs, dialysis access catheters and conventional Vortex ports, partially offset by increased unit sales of Venacure/EVLT procedure kits and lasers and Smart ports. Oncology/Surgery sales were $13.7 million, a decrease of 16% from prior year sales of $16.3 million. The decrease was primarily due to the decrease in LC Beads sales described earlier. Nanoknife sales totaled $2.0 million in the third quarter of fiscal 2012 and $1.9 million in the prior year quarter.

From a geographic perspective, U.S. sales decreased $4.7 million or 10% in the third quarter of fiscal 2012 to $43.6 million from $48.3 million a year ago. This decrease was primarily due to decreased unit sales of LC Beads and PICCs, partially offset by increased unit sales of Venacure/EVLT procedure kits, lasers and Smart ports. International sales were $7.9 million in the fiscal third quarter of 2012, an increase of 26% from $6.3 million in the comparable prior year period. Increased unit sales of Nanoknife, RF ablation and Venacure/EVLT procedure kits were the sources of this increase.

Gross profit. Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Our gross profit as a percentage of sales decreased to 57.0% in the third quarter of 2012 from 58.0% in the same quarter a year ago. The decrease in gross profit was primarily attributable to $912 thousand of expenses for our Quality Call To Action program to review and augment our Quality Management Systems and $438 thousand in expenses associated with the voluntary recall of Venacure EVLT NeverTouch procedure kits, Morpheus CT PICCs and DuraMax chronic Hemodialysis Catheters. The recalls stemmed primarily from defective component parts manufactured by suppliers. Additionally, we experienced a 2% decline in the average selling price of our products compared with the prior year period. This decline in gross profit was partially offset by material cost reduction programs and improved factory utilization.

Research and development expenses. Research and development (“R&D”) expenses include costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs and our intellectual property. R&D expenses decreased by $748 thousand, or 14%, to $4.6 million in the third quarter of fiscal 2012 compared to the same prior year period. The decrease in the current year quarter is due to higher prior year clinical research investments based on project timing, and the temporary reassignment of R&D personnel to operations to support the Quality Call to Action program. As a percentage of net sales, R&D expenses were 8.9% for the fiscal third quarter of 2012, compared with 9.7% for the same period a year ago.

Sales and marketing expenses. Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and samples. S&M expenses increased $1.2 million or 9% to $15.8 million in the third quarter of fiscal 2012 compared to the same prior year period. This increase is primarily due to increased International sales expenses as we expand our International sales activities, including our recent establishment of a direct sales office in the Netherlands, as well as increased sales expense in the U.S., primarily for enhanced commission programs. As a percentage of net sales, S&M expenses were 30.6% for the fiscal third quarter of 2012, compared with 26.6% for the prior year period.

General and administrative expenses. General and administrative (“G&A”) expenses include executive management, finance and accounting, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses increased $88 thousand, or 2%, to $4.4 million in the third quarter of fiscal 2012 compared to the prior year period, primarily due to expenses associated with increased headcount. G&A expenses increased to 8.6% of net sales compared with 8.0% in the prior year period.

Amortization of intangibles. Amortization of intangibles was $2.3 million in the third quarter of fiscal 2012, up $68 thousand over the comparable third fiscal quarter of 2011 primarily due to amortization of intangibles related to the February 2011 acquisition of certain business assets of our former distributor in the Netherlands. The prior year results had included amortization for the Medron Lightport technology, which we wrote off in the fourth quarter of fiscal 2011.

Acquisition, restructuring and other costs, net. The third quarter of fiscal 2012 included acquisition, restructuring and other costs of $5.0 million which primarily consisted of $3.8 million of expenses related to the proposed acquisition of Navilyst, and approximately $400 thousand each for expenses related to the closure of our manufacturing facility in the UK, expenses for transitions in the executive management team and other business development projects. The prior year period had no acquisition, restructuring and other costs.

Operating (loss) income. The third fiscal quarter of 2012 resulted in an operating loss of $2.8 million compared to operating income of $5.2 million for the third quarter of fiscal 2011. As a percentage of sales, the operating loss was (5.3)% for the third quarter of 2012 , compared to 9.6% in the same prior year period.

Other income (expenses). Other income and expenses for the third quarter of fiscal 2012 was $123 thousand of net expense compared with $178 thousand of net expense in the same period a year ago, representing (0.2)% and (0.3)% of net sales in their respective periods. Increased loss on interest rate swap and increased credit card fees are the primary factors causing the increase.

Income taxes. Our effective tax rate was a 39% benefit for the fiscal third quarter of 2012 compared with 25% for the prior year period. The three month period ending February 29, 2012 reflects a benefit from settling the New York State tax examination for the periods ending October 2004 to May 2008 which resulted in recording additional tax credits related to increasing employment in a New York State Empire Zone. The three month period ending February 28, 2011 reflects the benefit from the R&D tax credit that had temporarily expired but had been retroactively renewed during the quarter ended February 28, 2011.

Net (loss) income. For the third quarter of 2012, we reported net loss of $1.8 million, a decrease of $5.6 million from net income of $3.8 million for the prior year quarter.

Investment in Nanoknife Technology. The financial results of our Nanoknife program are recorded in our Oncology/Surgery division. Taking into account the sales and the related cost of sales and operating expenses, the net impact of our investment in Nanoknife technology in the third fiscal quarter of 2012 was $1.9 million of pretax loss and $1.3 million or ($0.05) per share after tax compared with $1.2 million on pretax income and $0.9 million or ($0.04) per share after tax in the third fiscal quarter of 2011.

### Nine Months ended February 29, 2012 and February 28, 2011

For the first nine months of fiscal 2012, we reported net income of $1.9 million, or $0.08 per diluted common share, on net sales of $164.1 million, compared with net income of $9.0 million, or $0.36 per diluted common share, on net sales of $159.5 million in the first nine months of the prior year.

The following table sets forth certain operating data as a percentage of net sales:

|  | Nine Months Ended Feb 29, 2012 | Feb 28, 2011 |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 57.8% | 58.5% |
| Research and development | 9.3% | 9.9% |
| Sales and marketing | 29.2% | 26.8% |
| General and administrative | 8.1% | 8.2% |
| Amortization of intangibles | 4.2% | 4.2% |
| Acquisition, restructuring and other costs, net | 4.5% | 0.5% |
| Operating income | 2.4% | 8.9% |
| Other income(expenses) | (0.7%) | (0.6%) |
| Income taxes | 0.5% | 2.6% |
| Net income | 1.2% | 5.6% |

Net sales. Net sales of $164.1 million increased $4.6 million from the $159.5 million reported in the first nine months of fiscal 2011. The change in net sales was primarily attributable to increased unit sales of Smart ports, LC Beads, Venacure/EVLT procedure kits and lasers and Smart ports, partially offset by decreased sales of our conventional Vortex ports and Benephit renal infusion products.

From a reportable segment perspective, Vascular sales increased 1% from the prior year period to $112.8 million. This increase was driven primarily by increased unit sales of Smart ports and Venacure/EVLT procedure kits and lasers, partially offset by 4% lower average selling prices. Oncology/Surgery sales were $51.3 million, an increase of 7% on prior year sales of $47.8 million. The increase was primarily due to increased unit sales of LC Beads and a 4% increase in average selling prices of Oncology/Surgery products, excluding LC Beads, partially offset by decreased unit sales of RF electrodes and Nanoknife generators. Nanoknife sales totaled $7.5 million in the first nine months of fiscal 2012 and $4.6 million in the prior year period.

From a geographic perspective, U.S. sales increased in the first nine months of fiscal 2012 to $140.6 million from $140.5 million a year ago. This increase is primarily attributable to increased unit sales of LC Beads partially offset by decreased sales of our RF product and a 4% decrease in the average selling price of our Vascular products. International sales were $23.5 million in the first nine months of fiscal 2012, an increase of 24% from $19.0 million in the comparable prior year period. Increased unit sales of our Oncology/Surgery products, led by Nanoknife products, were the primary source of this increase.

Gross profit. Our gross profit as a percentage of sales decreased to 57.8% in the first nine months of 2012 from 58.5% in the prior year period. The decrease in gross profit was primarily attributable to $912 thousand of expenses attributed to our Quality Call To Action

Program to review and augment our Quality Management Systems and $1.9 million in expenses associated with the voluntary recall of Venacure EVLT NeverTouch procedure kits, Morpheus CT PICCs and DuraMax chronic Hemodialysis Catheters. The recalls stemmed from defective component parts manufactured by suppliers. Additionally, we experienced a 3% decline in the average selling price of our products as compared with the prior year period. This decline in gross profit margin was partially offset by material cost reduction programs and improved factory utilization.

Research and development expenses. R&D expenses decreased by $535 thousand, or 3%, to $15.3 million in the first nine months of fiscal 2012 compared to the same prior year period. The decrease in the current year is due to higher prior year clinical research investments, primarily due to project timing and the temporary reassignment of R&D personnel to operations for the Quality Call to Action program. As a percentage of net sales, R&D expenses were 9.3% for the first nine months of fiscal 2012, compared with 9.9% for the same period a year ago.

Sales and marketing expenses. S&M expenses increased $5.2 million or 12% to $48.0 million in the first nine months of fiscal 2012 compared to the same prior year period. This increase is primarily due to increased sales commissions in the U.S. and increased International sales expenses as we expand our International sales activities, including our recent establishment of a direct sales office in the Netherlands. As a percentage of net sales, S&M expenses were 29.2% for the first nine months of fiscal 2012, compared with 26.8% for the prior year period.

General and administrative expenses. G&A expenses increased $266 thousand, or 2%, to $13.4 million in the nine months of fiscal 2012 compared to prior year period, primarily due to increased headcount and increased legal fees related to outstanding litigation, partially offset by lower stock based compensation expenses. G&A expenses decreased to 8.1% of net sales compared with 8.2% in the prior year period.

Amortization of intangibles. Amortization of intangibles was $6.9 million in the first nine months of fiscal 2012, up $254 thousand over the comparable 2011 period primarily due to amortization of intangibles related to the February 2011 acquisition of the assets and business of our former distributor in the Netherlands. The first nine months of fiscal 2012 also included amortization of the final payment related to the Flowmedica acquisition. The prior year results had included amortization for the Medron Lightport technology, which we wrote off in the fourth quarter of fiscal 2011.

Acquisition, restructuring and other costs, net. The first nine months of 2012 included acquisition, restructuring and other costs of $7.4 million which primarily consisted of $3.8 million of expenses associated with the proposed acquisition of Navilyst, $1.2 million associated with the closure of our facility in the UK, $1.0 million of expenses associated with the separation agreement with our former chief executive officer, $800 thousand of expenses for transitions in the executive management team, $400 thousand of expenses associated with other business development projects and $286 thousand of expenses for the relocation of our new chief executive officer partially offset by a gain of $201 thousand on the sale of assets related to the Centros product line. The prior year period included $772 thousand of expenses related to transitions in the executive management team.

Operating income. Operating income was $3.9 million and $14.1 million for the first nine months of fiscal 2012 and 2011, respectively. As a percentage of sales, operating income decreased to 2.4% compared with 8.9% in the prior year period.

Other income (expenses). Other income and expenses for the nine months ended February 29, 2012 was $1.1 million of net expense compared with $1.0 million of net expense in the same period a year ago, representing (0.7)% and (0.6)% of net sales in their respective periods.

Income taxes. Our effective income tax rate for the nine month periods ending February 29, 2012 and February 28, 2011 was 31% and 32%, respectively. The nine month period ending February 29, 2012 reflects a benefit from settling the New York State tax examination for the periods ending October 2004 to May 2008 which resulted in recording additional tax credits related to increasing employment in a New York State Empire Zone. The nine month period ending February 28, 2011 reflects the benefit from the R&D tax credit that had temporarily expired but had been retroactively renewed during the quarter ended February 28, 2011.

Net income. For the first nine months of fiscal 2012, we reported net income of $1.9 million, a decrease of $7.0 million from net income of $9.0 million for the prior year period.

Investment in Nanoknife Technology. The financial results of our Nanoknife program are recorded in our Oncology/Surgery division. Taking into account the sales and the related cost of sales and operating expenses, the net impact of our investment in Nanoknife technology in the first nine months of fiscal 2012 was $5.1 million of pretax loss and $3.5 million or ($0.14) per share after tax comparable to $4.3 million on pretax income and $2.9 million or ($0.12) per share in the same prior year period.

### Liquidity and Capital Resources

Our cash, cash equivalents and marketable securities totaled $143.0 million at February 29, 2012, compared with $131.5 million at May 31, 2011. Marketable securities consists of U.S. government issued or guaranteed securities, corporate bonds and auction rate securities. At February 29, 2012, total debt was $6.3 million comprised of short and long-term bank debt that financed our facility expansions in Queensbury, New York. This compared with $6.6 million at May 31, 2011.

Summary of cash flows (in thousands):

| Cash provided by (used in): | Nine Months ended Feb 29, 2012 | Feb 28, 2011 |
| --- | ---: | ---: |
| Operating activities | $12,502 | $21,973 |
| Investing activities | (25,440) | (47,338) |
| Financing activities | 1,003 | 1,817 |
| Effect of exchange rate changes on cash and cash equivalents | (2) | 42 |
| Net change in cash and cash equivalents | $(11,937) | $(23,506) |

Net cash provided by operating activities for the nine months ended February 29, 2012 was $12.5 million compared with $22.0 million in the prior year period. Cash generated from operating activities during the first nine months of fiscal year 2012 was primarily the result of net income and the effect on net income of non-cash items, such as depreciation and amortization, stock-based compensation and deferred income taxes and changes in working capital balances including $5.3 million in prepaids associated with federal and state income taxes, vendor downpayments and inventory to be returned as a result of the terminated LC Bead distribution agreement. The prior year period consisted of similar components with higher net income and deferred income taxes representing the primary difference between the periods.

Net cash used in investing activities was $25.4 million for the nine months ended February 29, 2012, compared with $47.3 million for the same prior year period. The net cash used in investing activities in the first nine months of 2012 consisted primarily of net purchases of marketable securities and available-for-sale short term investments. In the prior year period, the same net components consisted of larger net purchases resulting in the larger use of cash for that period.

Net cash provided by financing activities was $1.0 million for the nine months ended February 29, 2012 compared to $1.8 million for the comparable prior year period. The current year period consisted of higher proceeds from the exercise of stock options and employee stock purchase plan than the previous period, offset by the purchase of shares under the newly approved stock repurchase program initiated in October 2011.

In October 2011, our Board of Directors authorized the repurchase of up to $20 million of our common stock, prior to May 31, 2012. No shares were repurchased during the third quarter of fiscal 2012. During the nine month period ended February 29, 2012, we repurchased 142,305 shares at an average price of $14.79 and subsequently retired the shares. We do not expect to repurchase additional shares prior to the May 31, 2012 expiration date of the authorization.

### Agreement to Acquire Navilyst Medical

On January 31, 2012, we entered into a definitive stock purchase agreement to acquire privately-held Navilyst Medical, Inc. in a cash and stock transaction valued at $372 million on that date. Navilyst Medical is a global medical device company with strengths in the vascular access, interventional radiology and interventional cardiology markets.

AngioDynamics will fund the purchase price and related transaction costs using approximately $97 million of cash on hand and $150 million from a faulty-committed bank credit facility in the form of a new debt issuance and the issuance of common stock.

AngioDynamics will issue approximately 9.5 million shares of common stock to Avista Capital Partners and have fully diluted shares outstanding of approximately 34.8 million shares upon the transaction’s closing. Avista will hold approximately 27 percent of the outstanding common stock and will have the right to nominate for election two directors to fill 2 new seats on AngioDynamics’ existing Board of Directors. The Board of Directors of both companies have unanimously approved the proposed transaction, which is expected to close in May 2012, and is subject to customary closing conditions, clearance under certain antitrust guidelines and the approval of AngioDynamics’ shareholders. On March 30, 2012, we filed the definitive proxy statement requesting shareholder approval of the transaction.

After closing, AngioDynamics expects to have approximately $50 million in cash and liquid investments, $150 million in debt and a $50 million revolving credit facility with the committed banks.

### Microsulis Medical Ltd.

On March 22, 2012, we established a strategic relationship with Microsulis Medical Ltd., a U.K.-based company specializing in the minimally-invasive, microwave ablation technology for the coagulation of soft tissue which has systems in more than 80 hospitals worldwide.

The relationship includes a $5 million equity investment in Microsulis through the purchase of senior preferred stock, representing a 14.3% ownership position, exclusive distribution rights to market and sell their microwave ablation systems in all markets outside the United States from May 2012 through December 2013, and an exclusive option to purchase at any time until September 22, 2013, substantially all of the global assets of Microsulis Medical, Ltd.

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially from that disclosed in our Annual Report on Form 10-K for our fiscal year ended May 31, 2011.

We believe that our current cash and investment balances, together with cash generated from operations, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant additional acquisitions of other businesses or technologies for cash, we may require external financing. We cannot assure you that such financing will be available on commercially reasonable terms, if at all.

## Market risk

As filed, 2,530 characters.

We are exposed to market risk due to change in interest rates. To reduce that risk, we periodically enter into certain derivative financial instruments to hedge our underlying economic exposure. We use derivative instruments as part of our interest rate risk management strategy. The derivative instruments used are floating-to-fixed rate interest rate swaps, which are subject to cash flow hedge accounting treatment.

At February 29, 2012, we maintained variable interest rate financing of $6.3 million in connection with our facility expansions. We have limited our exposure to interest rate risk by entering into interest rate swap agreements with KeyBank under which we agreed to pay the bank fixed annual interest rates of 4.45% and 5.06% and the bank assumed our variable interest payment obligations under the financing.

In fiscal 2007 we began to make sales in currencies other than US dollars, particularly the Euro, GB pound and Canadian dollar. Approximately 5% of our sales in the first nine months of fiscal 2012 were denominated in currencies other than the US dollar, primarily the Euro and GB pound. We currently have no significant direct foreign currency exchange risk.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities (“ARS”) in order to generate higher than typical money market investment returns. ARS typically are high credit quality instruments, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids. Such instances are usually the result of a drastic deterioration of issuer credit quality. Should there be a failed auction, we may be unable to liquidate our position in the securities in the near term. We have $1.85 million in investments in two auction rate securities issued by New York state and local government authorities that have failed auctions. The authorities are current in their interest payments on the securities.

We are party to legal actions that arise in the ordinary course of business as described in Note K.

## Controls and procedures

As filed, 1,477 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us (including our consolidated subsidiaries) in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting in the fiscal quarter ended February 29, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### AngioDynamics, Inc. and Subsidiaries

## Risk factors

As filed, 693 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2011 and “Part II, Item 1A. Risk Factors” of our quarterly report on Form 10-Q for our fiscal quarter ended November 30, 2011 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk.

Filed Apr 9, 2012.
Source: SEC EDGAR, the filing index for accession 0001193125-12-155135. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
